Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 297.00
Bid: 290.00
Ask: 304.00
Change: 0.00 (0.00%)
Spread: 14.00 (4.828%)
Open: 297.00
High: 297.00
Low: 297.00
Prev. Close: 297.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

22 Jan 2020 17:11

RNS Number : 6469A
MaxCyte, Inc.
22 January 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

 

Maxcyte Inc

54930053YHXULRFCU991

 

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

 

Legal & General Group Plc (Group)

 

Legal & General (Unit Trust Managers) Limited

 

City and country of registered office (if applicable)

1 Coleman St, London EC2R 5AA

4. Full name of shareholder(s) (if different from 3.)v

Name

 

Legal & General Assurance Society (LGAS)

 

Legal & General Assurance

(Pensions Management) Limited (PMC)

 

City and country of registered office (if applicable)

1 Coleman St, London EC2R 5AA

5. Date on which the threshold was crossed or reachedvi:

 

20 January 2020

 

6. Date on which issuer notified (DD/MM/YYYY):

 

22 January 2020

 

 

 

 

 

 

 

 

 

7. Total positions of person(s) subject to the notification obligation

 

 

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

Below 5%

-

Below 5%

57,403,583

Position of previous notification (if

applicable)

8.05%

-

8.05%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

ORD USD 0.01

(UTM)

-

 

Below 5%

 

-

Below 5%

SUBTOTAL 8. A

 

Below 5%

 

Below 5%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

 

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

Legal & General Group (Direct/Indirect)

5.26%

5.26%

 

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

5.26%

5.26%

 

Legal & General Group (Direct)

Below 3%

Below 3%

 

Legal & General Assurance Society (Direct)

 

Below 3%

 

Below 3%

 

 

Legal & General Group (Direct/Indirect)

 

5.26%

 

5.26%

 

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

5.26%

5.26%

Legal & General Group (Direct)

Below 3%

Below 3%

Legal & General Assurance (Pensions Management) Limited

(Direct)

Below 3%

Below 3%

Legal & General Group (Direct/Indirect)

 

5.26%

 

5.26%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

5.26%

5.26%

Legal & General Group (Direct/Indirect)

 

5.26%

 

5.26%

Legal & General Investment Management Limited (Indirect)

5.26%

5.26%

Legal & General Group (Direct/Indirect)

 

5.26%

 

5.26%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

5.26%

5.26%

Legal & General (Unit Trust Managers) Limited (Indirect)

Below 5%

Below 5%

Legal & General Group (Direct/Indirect)

 

5.26%

 

5.26%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

5.26%

5.26%

Go ETF Solutions

Below 5%

Below 5%

 

 

 

10. In case of proxy voting, please identify:

 

Name of the proxy holder

N/A

 

The number and % of voting rights held

N/A

 

The date until which the voting rights will be held

N/A

 

 

 

 

 

 

 

 

11. Additional informationxvi

 

 

Notification using the total voting rights figure of 57,403,583

 

 

 

Place of completion

Brunel House, 2 Fitzalan Road, Cardiff, CF24 0EB

Date of completion

22/01/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLFLFIDLAIFFII
Date   Source Headline
11th Jan 20217:00 amRNSMyeloid Therapeutics Clinical & Commercial License
23rd Dec 20207:00 amRNSTrading Update
9th Nov 20201:00 pmRNSCARMA Cell Therapies at SITC 2020
9th Nov 20207:00 amRNSPresentations at Upcoming Virtual IR Conferences
2nd Nov 20203:52 pmRNSResult of AGM
22nd Oct 20206:22 pmRNSDisclosure of Remuneration for Non-Audit Services
14th Oct 20207:00 amRNSNotification of AGM and Audit Declaration
13th Oct 20207:00 amRNSMaxCyte announces leadership appointments
1st Oct 20207:00 amRNSDirector/PDMR Shareholding
21st Sep 20207:00 amRNSResults for the Six Months ended 30 June 2020
10th Sep 20201:42 pmRNSGrant of options
10th Sep 20207:00 amRNSHC Wainright & Co Virtual Conference Presentation
9th Sep 20207:00 amRNSAppointment of Amanda L. Murphy as CFO
2nd Sep 20202:57 pmRNSHolding(s) in Company
2nd Sep 20207:00 amRNSNotice of Half Year Results
18th Aug 20207:00 amRNSExpansion of CARMA’s Phase I Trial of MCY-M11
14th Aug 20207:00 amRNSHolding(s) in Company
16th Jul 20206:04 pmRNSDirector Dealings and Issue of Equity
15th Jul 20207:00 amRNSTrading Update
8th Jul 20207:00 amRNSAPEIRON Biologics Clinical and Commercial License
1st Jul 20207:00 amRNSBlock Listing Return & TVR
2nd Jun 20205:54 pmRNSHolding(s) in Company
28th May 20203:34 pmRNSHolding(s) in Company
26th May 20205:49 pmRNSHolding(s) in Company
26th May 20204:22 pmRNSHolding(s) in Company
26th May 20203:45 pmRNSHoldings in Company
21st May 20201:50 pmRNSResult of Special Meeting and Issue of Equity
14th May 20207:00 amRNSPoster Presentation on MCY-M11 at ASCO 2020
7th May 20207:00 amRNSLicense Agreement with Caribou Biosciences
1st May 20207:00 amRNSResult of Offering
30th Apr 20205:39 pmRNSProposed Offering to raise up to £25.1 million
21st Apr 20207:00 amRNSFinal Results for Year Ended 31 December 2019
9th Apr 20207:00 amRNSBusiness Update Related to COVID-19 Pandemic
24th Mar 20207:00 amRNSLicense Agreement with Allogene Therapeutics
21st Feb 20207:00 amRNSConsolidation of Trading Lines
20th Feb 20206:18 pmRNSAIM Block Admission Return / Total Voting Rights
5th Feb 20207:00 amRNSMaxCyte to Present at BIO CEO & Investor Conf
24th Jan 20204:31 pmRNSGrant Of Options
22nd Jan 20205:15 pmRNSHolding(s) in Company
22nd Jan 20205:11 pmRNSHolding(s) in Company
22nd Jan 20205:08 pmRNSHolding(s) in Company
20th Jan 20207:00 amRNSTrading Update
19th Dec 20197:00 amRNSNew Executive Vice President and Trial Update
16th Dec 20195:25 pmRNSDirector/PCA transaction initial notification
4th Dec 20197:00 amRNSAgreement with KSQ Therapeutics
21st Nov 20197:00 amRNSVor Biopharma Clinical and Commercial License
14th Nov 20197:00 amRNSPresentation at Jefferies Healthcare Conference
7th Nov 20197:00 amRNSMaxCyte to Present at BIO-Europe 2019
1st Nov 20191:04 pmRNSResult of AGM
24th Oct 20197:00 amRNSMaxCyte Advances Phase I Clinical Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.